Drug Inverse Agonism
"Drug Inverse Agonism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Phenomena and pharmaceutics of compounds that bind to the same receptor binding-site as an agonist (DRUG AGONISM) for that receptor but exerts the opposite pharmacological effect.
| Descriptor ID |
D054314
|
| MeSH Number(s) |
G07.690.812.240.393 G07.700.680.240.393
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Inverse Agonism".
Below are MeSH descriptors whose meaning is more specific than "Drug Inverse Agonism".
This graph shows the total number of publications written about "Drug Inverse Agonism" by people in UAMS Profiles by year, and whether "Drug Inverse Agonism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Inverse Agonism" by people in Profiles over the past ten years.
-
Franks LN, Ford BM, Fujiwara T, Zhao H, Prather PL. The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. Toxicol Appl Pharmacol. 2018 08 15; 353:31-42.
-
Franks LN, Ford BM, Madadi NR, Penthala NR, Crooks PA, Prather PL. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs. Eur J Pharmacol. 2014 Aug 15; 737:140-8.